In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

ARWR — Advancing RNAi Therapies Across Multiple Disease Markets Arrowhead Pharmaceuticals NASDAQ:ARWR is a leading RNA interference (RNAi) therapeutics company utilizing its proprietary TRiM™ platform to develop precision medicines targeting cardiometabolic, liver, pulmonary, and rare diseases. Key Catalysts: Commercial milestone with REDEMPLO®: The launch of REDEMPLO® (plozasiran) for familial chylomicronemia syndrome (FCS) marks Arrowhead’s transition into a commercial-stage biotechnology company, validating both its RNAi technology and development strategy. Major Phase 3 opportunities: Upcoming SHASTA-3 and SHASTA-4 Phase 3 trials in severe hypertriglyceridemia represent important regulatory and commercial catalysts that could significantly expand plozasiran’s addressable market. Deep metabolic disease pipeline: Arrowhead maintains a strong portfolio across obesity, MASH, metabolic disorders, and liver diseases, providing multiple potential value drivers. Promising early-stage candidates: Programs such as ARO-INHBE and ARO-ALK7 have demonstrated encouraging early data, supporting future opportunities in obesity and metabolic disease treatment. Platform diversification: The TRiM™ platform enables the company to efficiently develop targeted RNAi therapies across multiple therapeutic areas, reducing dependence on a single product. Investment Outlook: Bullish above: $63.00–$64.00 Upside target: $105.00–$110.00 Supported by commercial execution, late-stage clinical catalysts, and a diversified RNAi pipeline, Arrowhead is positioned as a leading player in next-generation genetic medicines. 📢 ARWR — Combining commercial momentum with a broad RNAi pipeline to drive the next phase of precision medicine.

by Richtv_official

Breaking: Arrowhead Pharmaceuticals, Inc. (ARWR) Spike. 23%Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR ) stock spike 23% amidst earnings beat. The asset broke out of a bullish symmetrical triangle to claim the $50 resistant point after earnings report. Arrowhead Pharmaceuticals ( ARWR) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release. A flying arrow The previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of licensing and collaboration funds, which was significantly higher than the $3.6 million reported in 2024. The most significant event for Arrowhead hasn't been its annual earnings release, though. Earlier this month, the U.S. Food and Drug Administration (FDA) approved its Redemplo for the treatment of adults with familial chylomicronemia syndrome (FCS). This is a rare genetic disorder that impairs the body's ability to metabolize fats. Redemplo is Arrowhead's first FDA nod. Financial Performance In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024. About ARWR Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.

ARWR 1Y Stoch RSI is overbought, so it might have a little dip. 5Y Stoch RSI is looking bullish for a recovery bounce towards the 200 EMA around $30. ALL Stoch RSI appears to be in a bullish position. Prediction: we will soon see some bullish movement.

Arrowhead Pharma Stock Quote | Chart & Forecast Summary Key Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Arrowhead Pharma Stock Quote - Double Formation * Trend Line 1 & 2 | Completed Survey | Subdivision 1 * (Neckline) | Pattern Confirmation | Subdivision 2 - Triple Formation * Retracement 1 & 2 Numbered | Entry Survey Condition * Pattern Confirmation | At 23.00 USD * Daily Time Frame | Settings | Subdivision 3 Active Sessions On Relevant Range & Elemented Probabilities; European Session(Upwards) - US-Session(Downwards) - Asian Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell

by UnknownUnicorn87383881

$ARWR Data Catalyst to start September Like shares, leaps, and September 20th 25C's at .65 a contract RNA company with one of the largest pipelines in the industry, biotech sector likely to see a tailwind in markets with rates coming down over the next 12 months

by ClassicEquity

ARWR, preppin for a series of Price Growth..ARWR daily data is conveying significant accumulation at the current price range. Daily Higher lows on histogram and price has been registered confirming the current levels as the new base for the next series of ascend. Expect some series of price growth in the next few days. Spotted at 35.0 TAYOR. Safeguard Capital always.

Nice setup to $60 This has completed W2 correction and found support at the 38% FR

ARWR having good supply zones and short trades can be planned ARWR unable to make higher highs Recent fall from earnings if that gap being retested and rejected , planning to enter short if the gap is respected but RR is not great. so will take small position if possible.

by praveen.casimir

ARWR - A Successful Falling Wedge A Successful Falling Wedge Falling Wedges are prone to break out to the upside A bullish pattern and a bullish trend reversal result

arwr sell ▪️probitie silnim barom ▪️3 bara protiv trenda - razvorot ▪️AO v zone ............

by VaniaDichenkov

40.Break under 59. on SOW would give us even more confidence that it is in fact starting to move toward the 40. area. Since when under the 70. area on the 6th July after the print of a bearish engulf. with major supply presence., price made attempts to break to the upside with failure to do so. For more development about it just holla in the comments.

Arrowhead Pharmaceuticals The price formed a nice cup and handle pattern and also broke a recent bull flag. Due to the fact that we are at a significant resistance area I would consider to enter the trade when we close in combination with a high volume over 90$. The price target is 120$ (1:1 projection of the range of the cup and handle pattern) and the stop should be placed at the recent distinct low. The parabolic SAR daily chart default settings can be used as stopmanagement.

by Cape-Peninsula-Capital

ARWR 20+ Year Breakout Monthly candle close above $87 very bullish, extremely wavy development

$ARWR + Stocks I'm looking to get into immediately.All long positions for the following: Markups as requested. I can only do 10 posts in a 24 hour period which is a limiting factor. I'm not usually bogged down with requests. I'm not saying I want to be bogged down, but I kind of like doing these. They are like crossword puzzles or sudoku for me. Except I suck crosswords and sudoku. They are like a fun puzzle for me is a better phrasing. I actually don't enjoy puzzles though. Idk maybe you get what I'm going for. --------- AAL ADP ARWR BEAM CNNE ESRT GMBL GRUB TCOM THS VSAT

Playing with my new bullish divergence scanner. ARWR.The way this scanner works is by searching based off of indicators, so the indicators are going to favor our pre-existing ideas about what the stock should do. Be careful to run through more checks before you decide you like the stock. Here is the scanner code I'm using in stockchart.com's technical scan workbench: and and and and and and and and and and ----- Anybody have a different scan criteria they found that works well for them? Am I the last living human being on a sun scorched planet?

$ARWR Long Position Taking a long position with a stop limit order right above the previous day high @ $69.48 TP @ $81.10 SL @ $66.84

by Need4SpeedCA

ARWR 🌦Bear flag inside an irregular flat correction wave. Health sector is looking bullish, I expect ARWR to follow suit. Markets tend to follow other markets.

by DudeDiligence

$ARWR - target $87.82 Should this break out of the pennant, seems low probability, it would be a place to enter. Use a limit-stop order so that you don't miss the move if you are worried about missing it.

$ARWR - bull pennant after earnings I like the bull pennant and MACD, ATR and stochastic are all ok. Alerts are set to detect a break out. Looks strong.

$ARWR Cup and handle with pennant breakout, looking to buy the next dip targets $126

ARWR Cup and handle formation ARWR Cup and handle formation Looking for the pull back in the $60 range. Looking for EMA support. Potential big mover Short term short Long term long

by autopilot369

Arwr cup and handle Good candidate

by FreeBillyMcFarland